1. Wintrobe MM. Chronic lymphocytic leukemia. Lee GR, Bithell T C, Foster J, Athens J, Lukens J, editors. Wintrobe's clinical hematology. 9th ed.Philadelphia, United States of America: Lea and Febiger;2006. p. 2034–53.
2. Ahn YO, Koo HH, Park BJ, Yoo KY, Lee MS. Incidence estimation of leukemia among Koreans. J Korean Med Sci. 1991; 6:299–307.
Article
3. Kipps TJ. Chronic Lymphocytic Leukemia and Related Diseases. Lichtman Marshall A., Ernest Beutler, Kipps Thomas J., Uri Seligsohn, Kenneth Kaushansky, editors. Williams Hematology. 7th ed.New York, United States of America: McGraw-Hill;2006. p. 1362.
4. Parekh K, Rusch V, Kris M. The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia. Cancer. 1999; 86:1720–23.
Article
5. Dasanu CA, Alexandrescu DT. Risk for second non-lymphoid neoplasms in chronic lymphocytic leukemia. MedGenMed. 2007; 9:35.
6. Nam SH, Kwon JM, Mun YC, et al. A case of coexistent chronic lymphocytic leukemia and multiple myeloma. Korean J Hematol. 2005; 40:41–4.
Article
7. Lee JL, Kang HJ, Oh HA, et al. A case of pure red cell aplasia associated with b-cell chronic lymphocytic leukemia. Korean J Hematol. 2002; 37:60–4.
8. Lee SA, Kim YJ, Lim KC, et al. A case of adenocarcinoma of the lung in patient with chronic lymphocytic leukemia. J Korean Cancer Assoc. 1998; 30:613–9.
9. Schollkopf C, Rosendahl D, Rostgaard K, Pipper C, Hjalgrim H. Risk of second cancer in chronic lymphocytic leukemia. Int J Cancer. 2007; 121:151–6.
10. Potti A, Ganti AK, Koch M, Mehdi SA, Levitt R. Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia. Lung Cancer. 2001; 34:227–32.
Article
11. Wiernik PH. Second neoplasms in patients with chronic lymphocytic leukemia. Curr Treatment Options in Oncology. 2004; 5:215–23.
Article
12. Ravandi F, O'Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother. 2006; 55:197–209.
Article
13. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999; 17:2454–60.
Article
14. Ahn YJ, Kim YA, Hwang KT, Heo SC, Jung IM, Chung JK. Synchronous triple primary cancer with concomitant IPMN. J Korean Surg Soc. 2008; 75:70–5.
15. Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006; 98:15–25.
Article